Ulrich Lücking

Neglected sulfur(<scp>vi</scp>) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development

Ulrich Lücking · Organic Chemistry Frontiers · 2019 · 331 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Bayer Ag +13

Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis

Nina Douglas, Steven V. Ley, Ulrich Lücking et al. · Journal of the Chemical Society Perkin Transactions 1 · 1998 · 272 citations

Biosynthesis, Engineering, Biochemistry +12

Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates

Juan Alberto Sirvent, Ulrich Lücking · ChemMedChem · 2017 · 203 citations · Full text

Pharmaceutical Science, Drug Target, Bioorganic Chemistry +16

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 200 citations

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 176 citations · Full text